By Giulia Petroni 
 

Merck KGaA on Wednesday said that it has raised its forecast for the full year on the back of a strong performance in the third quarter.

The German pharmaceuticals-and-chemicals company said it expects net sales of between 19.30 billion euros and 19.85 billion euros ($22.37 billion-$23 billion), from previous guidance of EUR18.80 billion-EUR19.70 billion.

Adjusted earnings before interest, taxes, depreciation and amortization are seen at around EUR6 billion to EUR6.3 billion, from EUR5.6 billion-EUR6 billion previously. Adjusted earnings per share are expected at approximately EUR8.50-EUR9 from EUR7.80-EUR8.50 previously.

In the third quarter, Merck KGaA said sales were EUR4.97 billion. Adjusted Ebitda came in at EUR1.55 billion, while adjusted EPS came in at EUR2.24. The main driver was a strong operating performance from the life-science business, according to the company.

Merck KGaA is scheduled to release official results on Nov. 11.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

November 03, 2021 14:14 ET (18:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Merck KGAA.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Merck KGAA.